Featured New Products 2011

Highlighted products added to the Tocris Bioscience range during 2011

December 2011

Selective casein kinase 1ε inhibitor
4281 | PF 4800567

Displays 22-fold greater potency towards CK1ε than CK1δ (IC50 values are 32 and 711 nM for CK1ε and CK1δ respectively). ATP competitive. Displays minimal effect on the circadian clock.

Related Products: PF 670462 TAK 715 (R)-DRF053

Selective USP7 inhibitor
4285 | HBX 41108

Inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM). Displays uncompetitive inhibition. Also inhibits USP7-mediated p53 deubiquitination (IC50 = 0.8 μM). Stabilizes p53 and inhibits cancer cell growth; induces p53-dependent apoptosis in p53 wild type and null isogenic cancer cell lines.

Related Products: PSI PYR 41 IU1

Potent S1P1 agonist
4289 | RP 001

EC50 = 9 pM. Induces internalization and polyubiquitination of S1P1 in vitro. Selective for S1P1 over S1P2 - S1P4.

Related Products: VPC 23019 CYM 5442 SEW 2871

Selective activator of SK1 channels
4311 | GW 542573X

Activator of small-conductance Ca2+-activated K+ channels (SK, KCa2); selective for SK1 (EC50 = 8.2 μM in HEK293 cells expressing hSK1) with the profile hSK1 > hSK2 = hSK3 > hIK.

Related Products: NS 309 CyPPA SKA 31

November 2011

Potent and selective PLK1 inhibitor
4292 | SBE 13

IC50 values are 200 pM, 875 nM and 66 μM for PLK1, PLK3 and PLK2 respectively. Targets the inactive conformation of PLK1. Displays no effect on Aurora kinase A activity. Binds and stabilizes the inactive form of PLK1. Delays cell cycle progression, reduces cell proliferation and induces apoptosis in a range of human cancer cell lines.

Related Products: Wortmannin Cyclapolin 9 GW 843682X

KCNQ2/Q3 channel opener
4305 | ICA 069673

EC50 = 0.69 μM. 20-fold selective for KCNQ2/Q3 over KCNQ3/Q5 with no measurable activity over a panel of cardiac ion channels (IC50 > 30 μM for hERG, NaV1.5, L-type channels and KCNQ1). Orally active in several animal models of epilepsy.

Related Products: NS 5806 Kaliotoxin Margatoxin

Potent and selective inhibitor of AADACL1
4327 | JW 480

Inhibitor of the serine hydrolase enzyme KIAA1363 (AADACL1) (IC50 = 20 nM in mouse brain). Impairs migration, invasion, survival and tumor growth of prostate cancer cell lines in vivo. Reduces monoalkylglycerol ether (MAGE) levels.

Related Products: LDN 57444 SC 57461A (Z)-Pugnac

5-HT2A/D2 antagonist; atypical antipsychotic
4349 | Olanzapine

Ki values are 4 and 11 nM for 5-HT2A and dopamine D2 receptors respectively. Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, α1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM) . Atypical antipsychotic. Displays anticholinergic properties.

Related Products: Ziprasidone Zotepine

Potent VEGFR-1, -2 and -3 inhibitor
4350 | Axitinib

IC50 values are 0.2, 0.1 to 0.3, and 1.2 nM for VEGFR-2, VEGFR-3 and VEGFR-1 respectively. Inhibits angiogenesis and vascular permeability. Displays little activity at 'off-target' protein kinases and exhibits no significant activity in a broad protein kinase screen. Orally available.

Related Products: AP 24534 SU 5416 SU 6668

October 2011

Selective nonpeptide NTS1 antagonist
3721 | SR 48692

Neurotensin antagonist; selective for NTS1 over NTS2 (apparent affinity, Ke, is 36 nM for NTS1). Competitively inhibits binding of [125I]-neurotensin to HT29 and N1E115 cell membranes (IC50 values are 15.3 and 20.4 nM respectively). Orally bioavailable.

Related Products: SR 142948 Xenin 8 JMV 449

Potent voltage-dependent NaV1.8 channel blocker
4249 | A 887826

IC50 = 11 nM in recombinant human NaV1.8 channels. Reduces tactile allodynia in neuropathic rat models. 3- and 28-fold more potent at NaV1.8 channels compared to NaV1.2 and NaV1.7 channels respectively.

Related Products: A 803467 Ralfinamide mesylate ProTx II

Dual FAK/PYK2 inhibitor
4278 | PF 431396

Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively). Promotes osteoblast recruitment and activity, and stimulates bone formation in ovariectomized rats.

Related Products: FAK Inhibitor 14 PF 573228 A 419259

CXCR4 antagonist
4320 | FC 131

IC50 = 126 nM. Displays anti-HIV activity in assays using NL4-3 and IIIB strains (EC50 = 21 nM for both strains).

Related Products: AMD 3100 octahydrochloride WZ 811 Maraviroc

MGMT inhibitor
4359 | Lomeguatrib

Inhibitor of O6-methylguanine-DNA methyltransferase (MGMT); (IC50 = 0.009 μM in cell-free extracts from HeLa S3 cells); attenuates MGMT activity in vitro and in vivo. Enhances the antitumor activity of temozolomide (Cat. No. 2706) in both human melanoma and MCF-7 xenografts.

Related Products: 5-Azacytidine Decitabine RG 108

September 2011

Potent B-Raf inhibitor
2650 | SB 590885

Kd = 0.3 nM. Selective for B-Raf against 46 other kinases (Ki app values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively). Decreases anchorage-independent growth of melanoma cell lines. Inhibits ERK phosphorylation and proliferation in tumor cells expressing B-RafV600E.

Related Products: ZM 336372 L-779,450 GW 5074

Selective RARα antagonist
3660 | BMS 195614

Neutral antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) recruitment.

Related Products: BMS 753 AM 580 BMS 453

α7-selective agonist
3964 | AR-R 17779

Ki values are 190 and 16000 nM for rat α7 and α4β2 receptors respectively. CNS penetrant after systemic administration.

Related Products: PHA 543613 PNU 282987 TC 1698

Potent and selective ROCK inhibitor
4009 | GSK 269962

IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension.

Related Products: SB 772077B GSK 429286 Y-27632

Potent GPR17 agonist
4074 | PF9

Potent agonist of GPR17 (EC50 = 36 pM).

Related Products: CID 2745687 ML 145 TC-O 9311

August 2011

MDM2 antagonist
3984 | Nutlin-3

Inhibits the MDM2-p53 interaction (IC50 = 0.09 μM) and activates p53. Antiproliferative agent; induces apoptosis in cancer cells.

Related Products: Pifithrin-μ PRIMA-1 CP 31398

γ-secretase inhibitor
4000 | MRK 560

Inhibits proteolytic cleavage of amyloid precursor protein (APP) over the Notch pathway. Reduces levels of Aβ in the brain (inhibits Aβ40 and Aβ42 in SH-SY5Y neuroblastoma cells with an IC50 of 0.65 nM); attenuates plaque deposition. Orally bioavailable.

Related Products: Begacestat BMS 299897 L-685,458

Potent and selective PLD2 inhibitor
4171 | VU 0364739

IC50 = 20 nM; displays 75-fold selectivity against PLD1 (IC50 = 1500 nM).

Related Products: VU 0155069 YM 26734 LY 311727

Potent ATM kinase inhibitor
4176 | KU 60019

IC50 = 6.3 nM. Exhibits little to no nonspecific target effects against a panel of 229 protein kinases; displays similar target selectivity to KU 55933 (Cat. No. 3544). Inhibits migration and invasion of human glioma cells in vitro.

Related Products: PHA 665752 KU 55933 Mirin

MCH1 antagonist
4242 | GW 803430

IC50 = 9.3 nM. Displays antiobesity and antidepressant-like effects in rats and mice. Orally active.

Related Products: BMS 470539 ATC 0175 SNAP 94847

July 2011

Induces endoderm formation in ESCs
4015 | IDE 1

EC50 = 125 nM. Thought to activate the TGF-β signaling pathway; induces Smad2 phosphorylation and increases levels of Nodal expression.

Related Products: TWS 119 Stauprimide Dexamethasone

Highly selective c-Met inhibitor
4239 | PF 04217903 mesylate

High affinity; Ki = 6-7 nM against wild type c-Met. Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.

Related Products: PHA 665752 SU 5416 SU 11274

Selective mTOR inhibitor
4248 | Torin 2

IC50 = 2.1 nM. Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Orally available.

Related Products: PI 103 KU 0063794 Compound 401

Potent and selective GPR139 agonist
4255 | TC-O 9311

EC50 = 39 nM in CHO-K1 cells expressing human GPR139. Displays no activity against a range of 90 diverse targets.

Related Products: ML 145 Kynurenic acid NPPB

June 2011

RXR agonist
4064 | Fluorobexarotene

Ki = 12 nM; EC50 = 43 nM at RXRα receptors. Displays similar RAR agonist activity to bexarotene; exhibits an apparent RXR binding affinity 75% greater than bexarotene.

Related Products: LG 101506 UVI 3003 Docosahexaenoic acid

Akt kinase inhibitor
4144 | GSK 690693

ATP-competitive pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition for AMPK, PKA and PAK and PKC isoforms (IC50 < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.

Related Products: API-2 10-DEBC FPA 124

High affinity H3 receptor antagonist
4020 | JNJ 5207852

pKi values are 8.9 and 9.2 in rat and human respectively. Brain penetrant and orally active. Has 3- and 100-fold higher affinity than thioperamide (Cat. No. 0644) for rat and human H3 receptors respectively. Suppresses slow-wave sleep; exhibits wake-promoting effects in rodent arousal models.

Related Products: Imetit Clobenpropit JNJ 10181457

Potent, selective Aurora kinase A inhibitor
4066 | TC-A 2317

Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B. Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.

Related Products: ZM 447439 NSC 95397

Dual specificity PPARα/γ agonist
3965 | Tesaglitazar

IC50 values are 0.35 and 3.8 μM for PPARγ and PPARα respectively. Prevents atherosclerosis progression in E3L.CETP transgenic mice. Also reduces insulin resistance in obese Zucker rats. Orally active.

Related Products: CP 775146 WY 14643 Troglitazone

May 2011

Src tyrosine kinase inhibitor
3963 | AZM 475271

Reduces tumor size, vascularity and metastasis, and increases apoptosis in human pancreatic cells grown in nude mice. Also exhibits antiangiogenic activity in vitro and in vivo. Sensitizes tumor cells to the cytotoxic effects of gemcitabine (Cat. No. 3259).

Related Products: A 419259 PD 166285 1-Naphthyl PP1

Potent and selective MAGL inhibitor
3836 | JZL 184

Blocks hydrolysis of the endocannabinoid 2-arachidonyl glycerol (2-AG) in vivo in the mouse brain (IC50 = 8 nM). Potentiates depolarization-induced suppression of excitability in cerebellar Purkinje neurons. Exhibits >300-fold selectivity for MAGL over FAAH in vitro.

Related Products: Pristimerin GSK 264220A

Selective MEK inhibitor
4237 | PD 184352

Ki = 300 nM in vitro. Suppresses FGF-mediated angiogenesis in vivo and decreases VEGF expression. Enhances the therapeutic efficacy of taxol (Cat. No. 1097) in vivo. Orally active.

Related Products: PD 0325901 PD 198306 U0126

Potent and selective IKK-2 inhibitor
4238 | PF 184

IC50 = 37 nM. Displays selectivity over 85 other kinases. Inhibits IL-1β-induced TNF-α in a steroid-insensitive in vitro model of oxidative stress.

Related Products: SC 514 IMD 0354 IKK 16

Selective ERK5/BMK1 inhibitor
4132 | XMD 8-92

KD values are 80, 190, 600 and 890 nM for BMK1, DCAMKL2, PLK4 and TNK1 respectively. Displays selectivity over 402 diverse kinases. Blocks growth factor-induced activation of cellular BMK1 and reduces BMK1 activity in in vitro kinase assays. Also reduces BMK1-dependent transactivating activity of MEF2C. Blocks tumor cell proliferation and tumor-associated angiogenesis.

Related Products: TMCB FR 180204

April 2011

Non-competitive AMPA receptor antagonist
2555 | GYKI 53655

Non-competitive AMPA and kainate receptor antagonist. Analog of GYKI 52466 (Cat. No. 1454). Prolongs the survival time after MgCl2- induced global cerebral ischemia. Exhibits anticonvulsant activity. Also blocks GluK3 homomeric receptors (IC50 = 63 μM) and GluK2b(R)/GluK3 heteroreceptors (IC50 = 32 μM) at high concentrations.

Related Products: Naspm CP 465022 ZK 200775

Potentiator of α7 nAChRs
4141 | LY 2087101

Allosteric potentiator of α7, α4β2 and α4β4 nAChRs; displays selectivity against α3β4 nAChRs. Thought to potentiate agonist-evoked α7 responses by binding within the nAChR transmembrane region.

Related Products: CCMI Ivermectin NS 1738

Selective and potent COX-2 inhibitor
4206 | Valdecoxib

Selective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 μM for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.

Related Products: Niflumic acid Resveratrol SC 236

Selective NR1/NR2A receptor antagonist
4154 | TCN 201

NMDA receptor antagonist selective for NR1/NR2A over NR1/NR2B-containing receptors (pIC50 values are 6.8 and <4.3 respectively in human recombinant NR1/NR2A and NR1/NR2B FLIPR/Ca2+ assays).

Related Products: D-AP5 CGP 37849 Gavestinel

Inhibitor of RNA helicase A (RHA)
4067 | YK 4-279

Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. Inhibits Ewing"s sarcoma family tumor (ESFT) cell growth; induces apoptosis.

Related Products: Cordycepin Actinomycin D Daunorubicin

March 2011

Potent cyclin-dependent kinase (cdk) 1, 2 and 9 inhibitor
3968 | AZD 5438

IC50 values are 16, 6 and 20 nM respectively. Exhibits antiproliferative activity in human tumor cell lines. Blocks cell cycling at G2-M, S and G1 phases; reduces the proportion of actively cycling cells in vivo.

Related Products: Purvalanol B PHA 767491 (R)-DRF053

Selective NPY Y2 antagonist
4018 | JNJ 5207787

IC50 = 0.1 μM. Displays 100-fold selectivity over NPY Y1, Y4 and Y5 receptors; also displays selectivity against a panel of 50 receptors, ion channels and transporters. Brain penetrant.

Related Products: BIIE 0246 S 25585 BIBO 3304 trifluoroacetate

Selective inhibitor of MEK1/2
4192 | PD 0325901

Inhibits MEK activity in mouse colon 26 cells (IC50 = 0.33 nM). Inhibits the growth of melanoma cell lines in vitro and in vivo; induces G1-phase cell cycle arrest and apoptosis in a mouse xenograft model. Also inhibits production of proangiogenic cytokines such as VEGF. Orally active.

Related Products: PD 198306 SL 327 U0126

Selective FAAH inhibitor
4175 | PF 3845

Ki = 0.23 μM. Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 μM).

Related Products: LY 2183240 JNJ 1661010 PF 750

Potent and selective NK3 antagonist
3297 | SSR 146977

Ki values are 0.26 and 19.3 nM in CHO cells expressing the human NK3 and NK2 receptor respectively. Also inhibits senktide (Cat. No. 1068) -induced inositol monophosphate formation and intracellular calcium mobilization (IC50 = 10 nM).

Related Products: SB 222200 SB 218795 Senktide

February 2011

CCR5 antagonist
3756 | Maraviroc

Displays potent anti-HIV-1 activity. Prevents the interaction of HIV-1 gp120 and CCR5 (IC50 = 6.4 nM), inhibiting HIV-1 entry. Also inhibits CCL3 (MIP-1α) binding to CCR5.

Related Products: RS 504393 AMD 3100 octahydrochloride BMS CCR2 22

Potent and selective p38α inhibitor
3915 | VX 745

IC50 = 10 nM. Also blocks TNFα production in LPS-stimulated HWB in vitro (IC50 = 177 nM). Displays 1000-fold selectivity over closely related kinases, including ERK1, MK2 and JNK1-3.

Related Products: SB 203580 SB 203580 SB 239063

Monopolar spindle 1 (Mps1) kinase inhibitor
3994 | AZ 3146

IC50 = 35 nM. Displays selectivity over 46 other kinases including Cdk1 and aurora kinase B. Interferes with chromosome alignment and overrides spindle assembly checkpoint. Inhibits the recruitment of Mad1, Mad2 and centromere protein E (CENP-E) to kinetochores.

Related Products: Go 6976 Monastrol Vinorelbine ditartrate

Selective TRPV4 antagonist
4100 | HC 067047

Reversibly inhibits currents through mouse, human and rat TRPV4 orthologs (IC50 values are 17, 48 and 133 nM). Also inhibits the endogenous TRPV4-mediated response to 4α-PDH (IC50 = 22 nM). Selective for TRPV4 over TRPV1, TRPV2, TRPV3 and TRPM8 channels.

Related Products: Capsazepine Anandamide SB 366791

Selective PPARγ agonist
4124 | Pioglitazone

EC50 = 0.69 μM. Thiazolidinedione (TZD) derivative and antidiabetic agent; improves insulin sensitivity.

Related Products: nTZDpa GW 1929 Troglitazone

January 2011

Potent PI 3-kinase inhibitor
4026 | GSK 1059615

IC50 = 2 nM. Inhibits proliferation in BT474 cells and attenuates MAPK signaling.

Related Products: PI 103 LY 294002 PI 828

Potentiator of NMDA receptors containing NR2C/NR2D
4105 | CIQ

Increases channel opening efficiency and enhances NMDA receptor responses.

Related Products: IEM 1460 PPDA Ro 25-6981

Potent and selective CRF1 antagonist
3294 | SN 003

Ki values are 3.4 and 7.9 nM at rat and human CRF1 respectively. Displays >1000-fold selectivity over CRF2 receptors. Suppresses CRF-induced ACTH release in vitro (IC50 = 241 nM) and is brain penetrant.

Related Products: NBI 27914 CP 154526 CP 376395

Potent and selective NaV1.7 channel blocker
4023 | ProTx II

IC50 = 0.3 nM. Shifts activation gating positively and decreases current magnitude. Displays 100-fold selectivity over other sodium channel subtypes.

Related Products: Tetrodotoxin citrate QX 314 chloride QX 314 bromide

Selective 5-HT6 antagonist
3688 | SGS 518

Useful for the treatment of cognitive impairment that is associated with schizophrenia and Alzheimer's disease.

Related Products: Ro 04-6790 SB 399885 SB 271046